-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Monoclonal B-cell hyperplasia (MBL) and chronic lymphocytic leukemia (CLL) are clonal B-cell diseases associated with an increased risk of infection and impaired immune response
.
A foreign research team studied the immunogenicity of recombinant shingles vaccine (RZV) in these patients
Monoclonal B-cell hyperplasia (MBL) and chronic lymphocytic leukemia (CLL) are clonal B-cell diseases associated with an increased risk of infection and impaired immune response
In the study, patients with MBL/untreated CLL and Bruton's tyrosine kinase inhibitor (BTKi) treated CLL were given two doses of RZV at an interval of two months
.
The anti-glycoprotein E enzyme-linked immunosorbent assay and the two-color IFN-γ and IL-2 fluorescent spot test were used to evaluate the response at 3 months and 12 months after the first injection of RZV, and were performed with a historical control group matched with age and sex Compare
Sixty-two patients (including 37 with MBL/untreated CLL and 25 with btki-treated CLL) were included in the study, and the median age at the time of vaccination was 68 years
.
The results showed that 45% of the participants had an antibody response at 3 months, which was significantly lower than the historical control group (63%, P=0.
In the end, only 29% of participants obtained a combined antibody and cellular response to RZV
.
Among the participants who underwent response assessment at 12 months (n=47), 24% of the antibody titers were below the response threshold
In summary, studies have shown that RZV does not produce cell-mediated antibody responses in MBL/CLL participants, which is comparable to age- and gender-matched antibody responses
.
This observation is mainly driven by the low response of patients treated with btki
RZV does not produce a cell-mediated antibody response in MBL/CLL participants, which is comparable to an age- and gender-matched antibody response
Original source:
Muchtar, E.
Muchtar, E.
, Koehler, AB, Johnson, MJ, Rabe, KG, Ding, W.
, Call, TG, Leis, JF, Kenderian, SS, Hayman, SR, Wang, Y.
, Hampel, PJ, Holets, MA , Darby, HC, Slager, SL, Kay, NE, Miao, C.
, Canniff, J.
, Whitaker, JA, Levin, MJ, Schmid, DS, Kennedy, RB, Weinberg, A.
and Parikh, SA (2021) , Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ajh.
26388 Leave a message here
